Catalent to Supply BeiGene’s Brukinsa
The companies announced a commercial supply agreement following FDA’s accelerated approval.
Catalent announced on Nov. 21, 2019 a commercial supply agreement with BeiGene, Ltd., for the manufacture of Brukinsa (zanubrutinib), a Bruton’s tyrosine kinase inhibitor that received accelerated approval by FDA on Nov. 14, 2019. The drug was approved as a treatment for mantle cell lymphoma in adult patients who have received at least one prior therapy.
In a press statement, Catalent reported that its Kansas City, MO site supported BeiGene’s program in formulation development, clinical trial supply, onto commercial supply for the United States.
“Our Kansas City facility has an extensive track record in supporting the development and launch of multiple fast-track designation medicines, especially cancer therapies,” commented Jonathan Arnold, president of Catalent’s Oral and Specialty Delivery business in the press statement. “We are pleased to have worked with BeiGene toward this important first approval and we look forward to commercial launch in the US, and to supporting BeiGene as they seek further approvals.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
